Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer

doi:10.1016/j.clinthera.2016.03.005

CNU IR > College of Smart Living > Dept. of Information Management > Periodical Articles > Item 310902800/30981

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/30981

Title:	Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer
Authors:	Leung, Henry W. C. Chan, Agnes L. F. Muo, Chih-Hsin
Contributors:	China Med Univ, An Nan Hosp, Dept Radiat Therapy Chia Nan Univ Pharm & Sci, Dept Informat Management China Med Univ, An Nan Hosp, Dept Pharm Chia Nan Univ Pharm & Sci, Dept Pharm China Med Univ Hosp, Management Off Hlth Data
Keywords:	cost-effectiveness economic evaluation locally advanced pancreatic cancer stereotactic body radiotherapy
Date:	2016-05
Issue Date:	2018-01-18 11:39:09 (UTC+8)
Publisher:	Elsevier
Abstract:	Purpose: The purpose of this study was to evaluate the cost-effectiveness of gemcitabine plus modern radiotherapy versus gemcitabine alone in the treatment of locally advanced pancreatic cancer in Taiwan. Methods: A Markov decision-analytic model was performed to compare the cost-effectiveness of 3 treatment regimens; gemcitabine alone (gem-alone), gemcitabine plus intensity-modulated radiotherapy (gem-IMRT), and gemcitabine plus stereotactic body radiotherapy (gem-SBRT). Patients transitioned between 5 health states: stable disease, local progression, distant metastasis, local and distant metastasis, and death. Findings: The incremental cost-effectiveness ratio for gem-IMRT and gem-SBRT compared with gem alone were NT$27,120,168 and NT$2,145,683 per quality-adjusted life-year gained, respectively. A willingness to pay threshold of 3 times the per capita gross domestic product was adopted according to the definition of the World Health Organization. The Taiwan per capita gross domestic product in 2015 was NT$673,920 (US$22,464; 1 NT$ = US$0.03333 in Taiwan); thus, a threshold was considered as NT $2,021,760 (US$67,392). The Monte-Carlo simulation found that the probability of cost-effectiveness at a willingness to pay threshold of NT$2,021,760 per quality-adjusted life-year was 0% chance for gem-IMRT and 50% for gem-SBRT. Implications: This study indicated that gem-IMRT or gem-SBRT in locally advanced pancreatic cancer is not cost-effective at a willingness to pay as defined by World Health Organization guideline in Taiwan. (C) 2016 Elsevier HS Journals, Inc. All rights reserved.
Relation:	Clinical Therapeutics, v.38 n.5, pp.1174-1183
Appears in Collections:	[Dept. of Pharmacy] Periodical Articles [Dept. of Information Management] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1699	View/Open

Loading...